Cleveland Clinic Abu Dhabi launches the world's first clinical AI scientist
Cleveland Clinic Abu Dhabi, in collaboration with Owkin, has launched Aila, the world’s first advanced clinical AI platform, a significant step that reinforces the UAE’s position in leveraging transformative technologies to advance healthcare and enhance data-driven medical research.The Aila platform is designed to support clinicians in making real-time clinical decisions and accelerate medical research using real patient data. This will help bridge the gap between scientific research and daily clinical practice, transforming complex medical data into actionable insights that support the quality and effectiveness of healthcare.
The platform will enable inference across vast and complex datasets, generate accurate medical insights, and continuously learn from available data. This will revolutionize how clinicians interact with clinical information, empowering them to make faster and more precise decisions when providing patient care.
Ayla acts as a clinical AI capable of connecting diverse datasets and unlocking their potential. Through a secure and intuitive natural language interface, it allows clinicians to query massive amounts of clinical data in real time, gaining insights that previously required days or weeks of manual review and analysis. It transforms fragmented information into a unified, queryable knowledge layer, providing valuable actionable insights that support clinical decision-making at critical moments.
George-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, affirmed that the launch of the "Ayla" platform embodies the hospital's commitment to pushing the boundaries of healthcare innovation and contributing to shaping the future of medical care. This is achieved by employing cutting-edge artificial intelligence technologies built upon real patient data, enabling medical professionals to make more accurate and efficient clinical decisions, enhancing opportunities for scientific discovery, and improving health outcomes for patients and communities.
He explained that the first phase of the platform's implementation will focus on prostate cancer, through the unification and analysis of multiple sources of clinical data, including electronic health records, physician notes, pathology reports, and medical imaging. This will allow for the development of an integrated knowledge system that supports medical decision-making and accelerates access to accurate clinical insights.
He added that the platform has the potential in the future to accommodate advanced types of data, including multi-omics data and genomic data, which enhances precision medicine applications and supports the development of more personalized and effective treatments for patients.

0 Comments